Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial
Mariette et al., The Lancet Rheumatology, doi:10.1016/S2665-9913(21)00315-5
https://c19early.org/mariette.html